Compare BWMN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMN | AKBA |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.2M | 729.1M |
| IPO Year | N/A | N/A |
| Metric | BWMN | AKBA |
|---|---|---|
| Price | $33.09 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $40.90 | $5.92 |
| AVG Volume (30 Days) | 117.1K | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.21 | $52.41 |
| Revenue Next Year | $9.62 | $21.57 |
| P/E Ratio | $35.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.90 | $1.15 |
| 52 Week High | $45.83 | $4.08 |
| Indicator | BWMN | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 34.58 |
| Support Level | $33.16 | $1.33 |
| Resistance Level | $36.67 | $1.60 |
| Average True Range (ATR) | 1.59 | 0.10 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 41.92 | 12.22 |
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.